
#video | Jan. 2021
Dr Mellor, Malaysia, explains why and how he is using immmunoscore in Stage III colon cancer patients

#video | Dec. 2020
Professor Yoshino, KOL in Asia region, talk about Immunoscore

#brochure | Nov. 2020
Brochure Immunoscore® in Localized Colon Cancer
For Patients & Caregivers (English)

#brochure | Oct. 2019
Brochure IVD Development
HalioDx provides flexible services for IVD assay development for companies in the diagnostics and pharma industries, for technology providers and for clinical labs.

#brochure | Nov. 2020
Leaflet Immunoscore® in High-risk Stage II Colon Cancer
For Healthcare Professionals (English version)

#brochure | Nov. 2020
Leaflet Immunoscore® in Stage III Colon Cancer
For Healthcare Professionals (Ennglish version)

#brochure | Nov. 2020
Leaflet Immunoscore® in Stage II Colon Cancer
For Healthcare Professionals (English version)

#brochure | Nov. 2020
Brochure Immunoscore® in Localized CC (CLIA US version)
For Healthcare Professionals (CLIA US version)

#brochure | Nov. 2020
Brochure Immunoscore® in Localized CC (CE/IVD version)
For Healthcare Professionals (CE/IVD version)

#poster | Nov. 2020
ASCO Quality Care Symposium on October 9-10, 2020
Impact of Immune Assessment with Immunoscore® on Patterns of Care In Stage II Colon Cancer

#video | Oct. 2020
Dr Tony Dhillon (UK) presenting Immunoscore at the Digestive Cancers Europe Scientific Update: Role of the Immune Response in Early Stage Colorectal Cancers

#video | Oct. 2020
Testimonial: Dr Su Pin Choo (Curie Oncology, Singapore) on the utility of Immunoscore in early stage Colon Cancer

#video | Oct. 2020
Managing colorectal cancer patients in the COVID-19 era with Drs Benjamin Weinberg (USA), Matías Chacón and Juan Manuel O’Connor (both Argentina)

#publication | Sep. 2020
Mlecnik B Bifulco C, Bindea G, et al.
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
J Clin Oncol.

#video | Aug. 2020
2’ to learn more Series: Jacques Fieschi PhD, VP, R&D, presents the R&D department and its technologies, with a focus on Brightplex®

#publication | Aug. 2020
El Sissy C, Kirilovsky A, Van den Eynde M et al.
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy
Clin Cancer Res

#publication | Aug. 2020
F Pages, J Taieb, P Laurent-Puig, and J Galon
The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions
OncoImmunology

#publication | Aug. 2020
Bruni D, K Angell H and Galon J
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer

#video | Jul. 2020
Immunoscore® highlights at ESMO GI. Presentations of Dr Le Bagousse and Jérôme Galon, PhD

#publication | Jul. 2020
A Lanzi,F.A Sinicrope, A.B Benson, and J Galon
The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
OncoImmunology

#publication | Jun. 2020
A Lanzi,F Pages, C Lagorce-Pages, and J Galon
The consensus immunoscore: toward a new classification of colorectal cancer
OncoImmunology

#poster | Jun. 2020
Unravelling the mystery of cancer-associated fibroblast (CAF) populations in the tumor microenvironment by a fully automated sequential chromogenic multiplex assay
AACR2020 Abstract # 5970

#publication | Jun. 2020
O’Connor JM, Esteso F & Chacón M
Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine
Future Medicine

#video | Jun. 2020
Webinar: Exploring Changes of Myeloid Cells with Chromogenic Multiplex IHC in Advanced Liver Cancer| Prof. Nagy Habibi & Jacques Fieschi, PhD

#video | Jun. 2020
Testimonial: Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) on the use of Immunoscore in routine practice in managing early Colon Cancer

#e-news | Jun. 2020
Factsheet Immunoscore® & COVID-19 Colon Cancer Guidelines

#poster | May. 2020
Poster presented at ASCO20 Virtual Scientific meeting#ASCO20
Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients
Abstract 4105

#publication | May. 2020
Marliot F, Chen X, Kirilovsky A et al.
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer
BMJ

#e-news | May. 2020
Expert Opinion: The Role of Microbiota and its Impact on the Tumor Microenvironment in Colorectal Cancer | Dr Benjamin A. Weinberg, MD, Oncologist in Georgetown, Washington DC

#video | May. 2020
2’ to learn more Series: Who are HalioDx solutions designed for? | Vincent Fert, President & CEO

#video | May. 2020
2’ to learn more Series: HalioDx presentation and the company's activities during COVID 19 Pandemic | Vincent Fert, President & CEO

#video | May. 2020
Webinar: Capturing the Complexity of the Tumor Microenvironment | Jérôme Galon, PhD & Jacques Fieschi, PhD

#e-news | Apr. 2020
Expert Opinion: Immunity and cancer | Dr Angela Alistar, MD, Oncologist in Morristown, NJ

#poster | Apr. 2020
Unravelling the mystery of cancer-associated fibroblasts (CAFs) populations in the tumor microenvironment by fully automated sequential chromogenic multiplex assay (AACR 2020)

#publication | Apr. 2020
Sinicrope F, Shi Q, Hermitte F et al.
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
JNCI Cancer Spectrum

#publication | Apr. 2020
Pages F, Andre T, Taieb J et al.
Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study
Annals of Oncology

#publication | Mar. 2020
Blair H
Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer
Molecular Diagnosis & Therapy volume

#video | Mar. 2020
Franck Pagès, MD, PhD, on Selecting Patients With Advanced Colon Cancer for Treatment

#poster | Jan. 2020
Poster presented at Gastro Intestinal Symposium #GI20
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study

#publication | Jan. 2020
Pagès F, Kirilovsky A, Mlecnik B et al.
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
Journal of Clinical Oncology

#poster | Dec. 2019
Poster presented at SITC 2019
Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.

#brochure | Nov. 2020
Brochure Immunoscore® in Localized Colon Cancer - SPANISH
For Patients & Caregivers (Spanish)

#video | Nov. 2019
Webinar: Evaluating Biomarkers During Clinical Trials for Immunotherapies. A Case Study on the Pioneer Project

#poster | Nov. 2019
Unveiling Tumor-Associated Macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay (SITC 2019)

#poster | Nov. 2019
Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture. (SITC 2019)

#poster | Nov. 2019
Poster presented at ESMO 2019 by Transgene
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.

#poster | Nov. 2019
Poster presented at SITC 2019
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.

#poster | Nov. 2019
Poster presented at ESMO 2019
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.

#video | Sep. 2019
Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem

#video | Sep. 2019
Webinar Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

#publication | Aug. 2019
Angell HK, Bruni D, Barrett JC et al.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.

#poster | Jul. 2019
Poster presented at ESMO GI 2019
Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

#publication | Jul. 2019
Mascaux C, Angelova M, Vasaturo A et al.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Nature

#video | Jul. 2019
HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment

#video | Jun. 2019
Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)

#video | Jun. 2019
Webinar on Brightplex®: Combining the power of multiplexing & the ease of chromogenic IHC to assess complex immune phenotype

#video | Jun. 2019
Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®

#poster | Jun. 2019
Poster presented at ASCO 2019
Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

#video | May. 2019
Discover HalioDx - Reportage by Grand Luminy Technopole - April 2017

#publication | May. 2019
Galon J & Bruni D
Tumor Immunology and Tumor Evolution: Intertwined Histories
Immunity

#publication | May. 2019
Pages F, Andre T, Taieb J et al.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology

#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jérôme Galon, PhD

#video | Apr. 2019
Immunogram Clinical Seminar (Atlanta, April 2019) | Jacques Fieschi, PhD

#poster | Apr. 2019
Validation of Brightplex®: a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment (AACR 2019)

#video | Apr. 2019
Dr. Fakih Discusses the Utility of Immunoscore® in CRC

#poster | Apr. 2019
Poster presented at AACR 2019
Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept

#poster | Apr. 2019
Poster presented at AACR 2019 by Lytix biopharma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma

#poster | Apr. 2019
Poster presented at AACR 2019 by Lytix biopharma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

#video | Mar. 2019
Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD

#publication | Mar. 2019
Zeitoun G, Sissy CE, Kirilovsky A et al.
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Chirurgia (Bucur).

#brochure | Mar. 2019
Brochure Clinical Research
HalioDx Biopharma Services

#publication | Mar. 2019
Galon J & Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.

#video | Jan. 2019
Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video

#poster | Jan. 2019
Poster presented at Gastrointestinal Cancers Symposium 2019
Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

#poster | Dec. 2018
Poster presented at ESMO ASIA 2018
UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

#poster | Dec. 2018
Poster presented at ESMO IO 2018
MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

#poster | Nov. 2018
Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®) (SITC 2018)

#poster | Nov. 2018
Poster presented at ESMO ASIA 2018
Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

#publication | Oct. 2018
Angelova M, Mlecnik B, Vasaturo A et al.
Evolution of Metastases in Space and Time under Immune Selection.
Cell

#poster | Oct. 2018
Poster presented at the CRI-CIMT-EATI-AACR 2018
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

#video | Aug. 2018
Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017

#video | Aug. 2018
Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016

#video | Aug. 2018
Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases

#video | Aug. 2018
Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD

#video | Aug. 2018
Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD

#poster | Jun. 2018
Poster presented at ASCO 2018 by Lytix biopharma
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors

#publication | May. 2018
Pagès F, Mlecnik B, Marliot F et al.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Lancet

#poster | Apr. 2018
Poster presented at AACR 2018
Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay

#poster | Feb. 2018
Poster presented at ASCO GI 2018
Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

#publication | Feb. 2018
Sinicrope F, Shi Q, Hermitte F et al.
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
J Clin Oncol.

#publication | Jan. 2018
Mlecnik B, Van den Eynde M, Bindea G et al.
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
J Natl Cancer Inst.

#publication | Dec. 2017
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.

#poster | Nov. 2017
Poster presented at SITC 2017 by Lytix biopharma
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study

#poster | Nov. 2017
Poster presented at SITC 2017
Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification

#poster | Sep. 2017
Poster presented at NSH 2017
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections

#poster | Jun. 2017
Poster presented at ASCO 2017
Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

#poster | Jun. 2017
Poster presented at ASCO 2017 by Kite Pharma

#poster | Jun. 2017
Poster presented at ASCO 2017 by Lytix biopharma
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study

#publication | May. 2017
Sinicrope F, Shi Q, Hermitte F et al.
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).
J Clin Oncol.

#publication | May. 2017
Galon J, Mlecnik B, Marliot F et al.
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
J Clin Oncol.

#poster | Apr. 2017
Poster presented at AACR 2017
A new standardized CD8 and PD-L1 dual assay

#poster | Nov. 2016
Poster presented at SITC 2016
Immunoscore® analytical performance

#publication | Sep. 2016
Hermitte F
Biomarkers immune monitoring technology primer: Immunoscore® Colon.
Journal for ImmunoTherapy of Cancer

#publication | Aug. 2016
Kirilovsky A, Marliot F, El Sissy C et al.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Int Immunol.

#publication | Mar. 2016
Mlecnik B, Bindea G, Angell HK et al.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Immunity

#publication | Feb. 2016
Mlecnik B, Bindea G, Kirilovsky A et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.

#publication | Jun. 2015
Berghoff AS, Fuchs E, Ricken G et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology

#publication | Oct. 2013
Bindea G, Mlecnik B, Tosolini M et al.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity

#publication | Jul. 2013
Galon J, Angell HK, Bedognetti D, Marincola FM
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity

#publication | Mar. 2012
Fridman WH, Pagès F, Sautès-Fridman C, Galon J.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.

#publication | Feb. 2011
Mlecnik B, Tosolini M, Kirilovsky A et al.
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
Journal of Clinical Oncology

#publication | Sep. 2006
Galon J, Costes A, Sanchez-Cabo F et al.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Science